Scholarlink

Background <p>Treatment of skeletal fragility in patients with pituitary diseases is challenging. Denosumab, an antiresorptive bone active drug, increased bone mineral density (BMD) and reduced incidence and risk of fractures in primary osteoporosis. This study aimed to evaluate the efficacy of denosumab in patients with pituitary disease-driven osteoporosis.</p> Methods <p>This retrospective study investigated the frequency of fragility fractures (FF) and the percent BMD changes at 1-, 2-, 5-, and 10-years of treatment with denosumab, in patients with osteoporosis due to secreting pituitary adenoma.</p> Results <p>Seventeen patients were included: 5 patients (29.4%) were affected by hyperprolactinemia due to PRL-secreting pituitary adenoma (PAs), six patients (35.3%) were affected by acromegaly and six patients (35.3%) by Cushing’s disease. Four patients carried prevalent-FF (23.5%). A single patient with acromegaly developed FF at 2 and at 5&#xa0;years of treatment with denosumab. Femoral neck BMD increased in 11 patients (64.7%) at 1&#xa0;year of treatment, in 9 patients (52.9%) at 2&#xa0;years of treatment, in 8 patients (47.1%) at 5&#xa0;years of treatment and in 2 patients (66.7%) at 10&#xa0;years of treatment. Lumbar spine BMD improved in all patients at 1&#xa0;year of treatment (100%), in 16 patients at 2&#xa0;years of treatment (100%), in 11 patients at 5&#xa0;years of treatment (100%), and in 2 patients at 10&#xa0;years of treatment (66.7%). No drug related adverse events occurred.</p> Conclusions <p>This study demonstrated for the first time that long-term treatment with denosumab is effective and safe in patients with osteoporosis due to secreting pituitary adenoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study

  • 期刊论文

  • 发表日期：

    2026年1月19日

查看全文
  • Sabrina Chiloiro,
  • Flavia Costanza,
  • Alessandra Vicari,
  • Antonella Giampietro,
  • Chiara Palumbo,
  • Amato Infante,
  • Consolato Gulli′,
  • Mario Rigante,
  • Pier Paolo Mattogno,
  • Laura De Marinis,
  • Alessandro Olivi,
  • Antonio Bianchi,
  • Francesco Doglietto,
  • Andrea Giustina,
  • Alfredo Pontecorvi

摘要

Background

Treatment of skeletal fragility in patients with pituitary diseases is challenging. Denosumab, an antiresorptive bone active drug, increased bone mineral density (BMD) and reduced incidence and risk of fractures in primary osteoporosis. This study aimed to evaluate the efficacy of denosumab in patients with pituitary disease-driven osteoporosis.

Methods

This retrospective study investigated the frequency of fragility fractures (FF) and the percent BMD changes at 1-, 2-, 5-, and 10-years of treatment with denosumab, in patients with osteoporosis due to secreting pituitary adenoma.

Results

Seventeen patients were included: 5 patients (29.4%) were affected by hyperprolactinemia due to PRL-secreting pituitary adenoma (PAs), six patients (35.3%) were affected by acromegaly and six patients (35.3%) by Cushing’s disease. Four patients carried prevalent-FF (23.5%). A single patient with acromegaly developed FF at 2 and at 5 years of treatment with denosumab. Femoral neck BMD increased in 11 patients (64.7%) at 1 year of treatment, in 9 patients (52.9%) at 2 years of treatment, in 8 patients (47.1%) at 5 years of treatment and in 2 patients (66.7%) at 10 years of treatment. Lumbar spine BMD improved in all patients at 1 year of treatment (100%), in 16 patients at 2 years of treatment (100%), in 11 patients at 5 years of treatment (100%), and in 2 patients at 10 years of treatment (66.7%). No drug related adverse events occurred.

Conclusions

This study demonstrated for the first time that long-term treatment with denosumab is effective and safe in patients with osteoporosis due to secreting pituitary adenoma.